These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23744427)

  • 1. Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance.
    Krysiak R; Gdula-Dymek A; Okopień B
    Pharmacol Rep; 2013; 65(2):429-34. PubMed ID: 23744427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance.
    Krysiak R; Gdula-Dymek A; Okopień B
    Pharmacol Rep; 2013; 65(5):1311-6. PubMed ID: 24399727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose.
    Krysiak R; Okopien B
    Atherosclerosis; 2012 Dec; 225(2):403-7. PubMed ID: 23107042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
    Krysiak R; Gdula-Dymek A; Okopień B
    Pharmacol Rep; 2013; 65(1):208-13. PubMed ID: 23563040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
    Krysiak R; Gdula-Dymek A; Okopien B
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):198-202. PubMed ID: 22935083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report.
    Krysiak R; Okopien B
    Atherosclerosis; 2010 Nov; 213(1):325-8. PubMed ID: 20705292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
    Krysiak R; Gdula-Dymek A; Okopien B
    Am J Cardiol; 2011 Apr; 107(7):1010-1018.e1. PubMed ID: 21276586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
    Okopień B; Krysiak R; Herman ZS
    J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
    Pruski M; Krysiak R; Okopien B
    Diabetes Care; 2009 Aug; 32(8):1421-4. PubMed ID: 19435959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.
    Krysiak R; Stachura-Kułach A; Okopień B
    Pharmacol Rep; 2010; 62(1):120-30. PubMed ID: 20360622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
    Belfort R; Berria R; Cornell J; Cusi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose.
    Krysiak R; Okopien B
    Metabolism; 2013 Jan; 62(1):39-43. PubMed ID: 22841520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.
    Krysiak R; Gdula-Dymek A; Okopien B
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1109-17. PubMed ID: 21630032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial.
    Gómez-Díaz RA; Talavera JO; Pool EC; Ortiz-Navarrete FV; Solórzano-Santos F; Mondragón-González R; Valladares-Salgado A; Cruz M; Aguilar-Salinas CA; Wacher NH
    Metabolism; 2012 Sep; 61(9):1247-55. PubMed ID: 22424822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of simvastatin on lymphocyte secretory function in patients with impaired fasting glucose.
    Krysiak R; Okopien B
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):491-7. PubMed ID: 21108528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial.
    Caballero AE; Delgado A; Aguilar-Salinas CA; Herrera AN; Castillo JL; Cabrera T; Gomez-Perez FJ; Rull JA
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3943-8. PubMed ID: 15292331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients.
    Krysiak R; Okopień B
    Pharmacol Rep; 2011; 63(1):95-101. PubMed ID: 21441616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
    Krysiak R; Okrzesik J; Szkrobka W; Okopień B
    Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.